Teva Pharma (TEVA) Tops Q1 EPS by 4c; offers guidance

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.52, $0.04 better than the analyst estimate of $0.48. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.98 billion.

GUIDANCE:

Teva Pharma sees FY2025 EPS of $2.45-$2.65, versus the consensus of $2.56. Teva Pharma sees FY2025 revenue of $16.8-17.2 billion, versus the consensus of $17.243 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Walmart to pay $1.4 billion for Vibe.co acquisition - WSJ
• SPS Commerce hires Morgan Stanley, explores sale - Reuters